Archive: Company News

Company News: Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.

— Multiple scientific conference contributions at ASM Microbe highlight benefits of Unyvero LRT

— First commercial evaluation agreements expected in the coming weeks

Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the U.S. commercial launch of its Unyvero sample-to-answer molecular diagnostic system and the Unyvero LRT Application Cartridge for lower respiratory tract infections at the ASM Microbe 2018 Congress in Atlanta, GA, USA (June 7-11). Curetis obtained regulatory clearance for the Unyvero System and Unyvero LRT from the U.S. FDA in April this year.

Read more…

Company News: BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced the appointment of Özlem Türeci,  M.D., as Chief Medical Officer, effective June 1, 2018. Dr. Türeci has chaired BioNTech´s Scientific and Clinical Advisory Board since the inception of the Company.

Read more…

Company News: ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer

ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018. He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013.

Read more…

Company News: Curetis Publishes Business and Financial Update for the First Quarter 2018

– Received U.S. FDA clearance for Unyvero System and LRT Cartridge

– Grew revenues in EMEA direct selling markets by 518% vs Q1 2017

– Closed EUR 4.1 million equity offering and gained access to additional USD 10 million equity facility

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the three months ended March 31, 2018.

Read more…

1 73 74 75 173